Aravive, Inc. (ARAV) financial statements (2020 and earlier)

Company profile

Business Address RIVER OAKS TOWER
HOUSTON, TX 77098
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments65454856576368
Cash and cash equivalents65454856576368
Receivables33311  
Prepaid expense1111000
Other undisclosed current assets0000001
Total current assets:68485257586368
Noncurrent Assets
Operating lease, right-of-use asset99  
Property, plant and equipment22220 1
Intangible assets, net (including goodwill)00000  
Intangible assets, net (excluding goodwill)00000  
Other noncurrent assets10100  
Other undisclosed noncurrent assets221212111111
Total noncurrent assets:14141515111112
TOTAL ASSETS:82636772697480
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3424234
Accounts payable1211001
Accrued liabilities1212133
Debt22     
Other undisclosed current liabilities  340  
Total current liabilities:5657234
Noncurrent Liabilities
Long-term debt and lease obligation88     
Operating lease, liability88  
Other undisclosed noncurrent liabilities00910877
Total noncurrent liabilities:89910877
Total liabilities:13151417101011
Stockholders' equity
Stockholders' equity attributable to parent69485355606469
Common stock0000000
Additional paid in capital539513513512511463462
Accumulated deficit(470)(466)(460)(457)(451)(400)(393)
Total stockholders' equity:69485355606469
TOTAL LIABILITIES AND EQUITY:82636772697480

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Gross profit:  32   
Operating expenses(5)(7)(7)(7)(53)(6)(9)
Other undisclosed operating income    1  
Operating loss:(5)(7)(4)(6)(51)(6)(9)
Nonoperating income (expense)11113(0)(0)
Investment income, nonoperating0000000
Other nonoperating income (expense)11112(1)(1)
Other undisclosed loss from continuing operations before equity method investments, income taxes    (2)  
Net loss available to common stockholders, diluted:(4)(6)(3)(5)(51)(7)(10)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net loss:(4)(6)(3)(5)(51)(7)(10)
Comprehensive loss, net of tax, attributable to parent:(4)(6)(3)(5)(51)(7)(10)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: